Clinical Trial Update: Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 [Phase 2]

View source ↗

Summary

A phase 2 update reports extended treatment and follow-up data for belumosudil in KD025-208 and KD025-213 for chronic graft-versus-host disease, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Belumosudil (Rezurock) (Belumosudil)

Snippet

Sponsor: Kadmon, a Sanofi Company | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: COMPLETED | Results posted: 2025-05-02